Walter Klemp Biography and Net Worth

Chairman of the Board, President and Chief Executive Officer of Moleculin Biotech

Mr. Klemp is a co-founder of our company and has served as our chairman of the board and Chief Executive Officer since July 2015 and as president since August 2017. Mr. Klemp has also served as Executive Chairman of the Board of Autonomix Medical, Inc. (Nasdaq: AMIX) since January 2022. From July 2018 until December 2021, Mr. Klemp served as executive chairman on the board of directors of Soliton, Inc., a medical device company focused on developing new technology for use in aesthetics. In December 2021 Soliton, Inc. was acquired by AbbVie, Inc. From November 2011 to July 2018, Mr. Klemp served as Chief Executive Officer of Soliton. Mr. Klemp served as president and Chief Executive Officer of Zeno Corporation from 2004 to April 2011, where he developed and marketed dermatology devices and drugs from concept through FDA approval and market launch. From 1987 to 2000, Mr. Klemp served as Chief Executive Officer and chairman of Drypers Corporation, a publicly traded multinational consumer products company that was listed as #1 on the INC 500 List of America’s Fastest Growing Companies. We believe that Mr. Klemp’s history with our company and background, coupled with his extensive experience in the medical field, provide him with the qualifications to serve as a Chairman of the Board and CEO.

What is Walter V. Klemp's net worth?: The estimated net worth of Walter V. Klemp is at least $13.25 thousand as of June 23rd, 2025. Mr. Klemp owns 29,744 shares of Moleculin Biotech stock worth more than $13,251 as of October 7th. This net worth estimate does not reflect any other assets that Mr. Klemp may own. Learn More about Walter V. Klemp's net worth.
How do I contact Walter V. Klemp?: The corporate mailing address for Mr. Klemp and other Moleculin Biotech executives is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. Moleculin Biotech can also be reached via phone at (713) 300-5160 and via email at [email protected]. Learn More on Walter V. Klemp's contact information.
Has Walter V. Klemp been buying or selling shares of Moleculin Biotech?: Walter V. Klemp has not been actively trading shares of Moleculin Biotech during the past quarter. Most recently, on Monday, June 23rd, Walter V. Klemp bought 27,027 shares of Moleculin Biotech stock. The stock was acquired at an average cost of $9.25 per share, with a total value of $249,999.75. Following the completion of the transaction, the chief executive officer now directly owns 29,744 shares of the company's stock, valued at $275,132. Learn More on Walter V. Klemp's trading history.
Who are Moleculin Biotech's active insiders?: Moleculin Biotech's insider roster includes Jonathan Foster (Executive VP & Chief Financial Officer), and Walter Klemp (Chairman of the Board, President and Chief Executive Officer). Learn More on Moleculin Biotech's active insiders.

Walter V. Klemp Insider Trading History at Moleculin Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/23/2025	Buy	27,027	$9.25	$249,999.75	29,744
12/26/2023	Buy	502	$258.75	$129,892.50	1,815
11/25/2022	Buy	120	$480.00	$57,600.00	1,093
11/21/2022	Buy	60	$431.25	$25,875.00	973
11/16/2022	Buy	227	$363.75	$82,571.25	847
5/11/2017	Buy	32	$303.75	$9,720.00

Walter V. Klemp Buying and Selling Activity at Moleculin Biotech

Moleculin Biotech Company Overview

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Today's Range

Now: $0.45

$0.44

$0.46

50 Day Range

MA: $0.62

$0.39

$1.36

2 Week Range

Now: $0.45

$0.16

$15.75

Volume

42,957 shs

Average Volume

647,549 shs

Market Capitalization

$8.67 million

P/E Ratio

N/A

Dividend Yield